For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
1
views
28
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      326
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Key Clinical Message

          This case report highlights the potential of belinostat for the treatment of relapsed/refractory peripheral T‐cell lymphomas, for which effective therapies are still scarce.

          Abstract

          Peripheral T‐cell lymphomas have an aggressive disease course associated with poor outcomes. We report a young patient with highly pretreated relapsed/refractory nodal follicular helper T‐cell lymphoma (angioimmunoblastic‐type [nTFHL‐AI]), who successfully received an allogeneic stem cell transplantation following belinostat therapy. The complete hematologic response achieved has lasted more than 2 years.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          GSCALite: a web server for gene set cancer analysis

          Chun-Jie Liu, Fei-Fei Hu, Meng-Xuan Xia … (2018)
          The availability of cancer genomic data makes it possible to analyze genes related to cancer. Cancer is usually the result of a set of genes and the signal of a single gene could be covered by background noise. Here, we present a web server named Gene Set Cancer Analysis (GSCALite) to analyze a set of genes in cancers with the following functional modules. (i) Differential expression in tumor versus normal, and the survival analysis; (ii) Genomic variations and their survival analysis; (iii) Gene expression associated cancer pathway activity; (iv) miRNA regulatory network for genes; (v) Drug sensitivity for genes; (vi) Normal tissue expression and eQTL for genes. GSCALite is a user-friendly web server for dynamic analysis and visualization of gene set in cancer and drug sensitivity correlation, which will be of broad utilities to cancer researchers.
          Article 0 comments Cited 466 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

            Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos … (2022)
            We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.
            Article 0 comments Cited 431 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Anticancer activities of histone deacetylase inhibitors.

              Jessica E. Bolden, Melissa J Peart, Ricky W Johnstone (2006)
              Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression. In addition, the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation. In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes associated with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclinical studies. However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood. Here we summarize recent advances in the understanding of the molecular events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.
              Article 0 comments Cited 152 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Vincent Camus:
                ORCID: https://orcid.org/0000-0002-1559-007X
                vincent.camus@chb.unicancer.fr
                Journal
                Journal ID (nlm-ta): Clin Case Rep
                Journal ID (iso-abbrev): Clin Case Rep
                Journal ID (doi): 10.1002/(ISSN)2050-0904
                Journal ID (publisher-id): CCR3
                Title: Clinical Case Reports
                Publisher: John Wiley and Sons Inc. (Hoboken )
                ISSN (Electronic): 2050-0904
                Publication date (Electronic): 23 June 2023
                Publication date Collection: June 2023
                Volume: 11
                Issue: 6 ( doiID: 10.1002/ccr3.v11.6 )
                Electronic Location Identifier: e7623
                Affiliations
                [ 1 ] Department of Hematology Centre Henri Becquerel Rouen France
                [ 2 ] Department of Genetic Oncology Centre Henri Becquerel Rouen France
                [ 3 ] Department of Pathology Centre Henri Becquerel Rouen France
                [ 4 ] INSERM U1245 Centre Henri Becquerel Rouen France
                Author notes
                [*] [* ] Correspondence

                Vincent Camus, Department of Hematology, Centre Henri Becquerel, rue d'Amiens, CS 11516, 76038 Rouen Cedex 1, France.

                Email: vincent.camus@ 123456chb.unicancer.fr

                Author information
                https://orcid.org/0000-0002-1559-007X
                Article
                Publisher ID: CCR37623 Other ID: CCR3-2023-04-0819.R1
                DOI: 10.1002/ccr3.7623
                PMC ID: 10290197
                SO-VID: 6900be41-78c6-4764-abc1-dcf144df9bb9
                Copyright © © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
                License:

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                Date revision received : 03 June 2023
                Date received : 27 April 2023
                Date accepted : 15 June 2023
                Page count
                Figures: 5, Tables: 0, Pages: 10, Words: 4951
                Funding
                Funded by: IDEOGEN AG
                Categories
                Subject: Case Report
                Subject: Case Report
                Custom metadata
                source-schema-version-number 2.0
                cover-date June 2023
                details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.9 mode:remove_FC converted:24.06.2023

                Keywords: allogenic stem cell transplantation,belinostat,complete response,hdac inhibitor,ntfhl‐ai,ptcl
                Data availability:
                Keywords: allogenic stem cell transplantation, belinostat, complete response, hdac inhibitor, ntfhl‐ai, ptcl

                Comments

                Comment on this article